Islam and coworkers reported that mice vaccinated with LNP-encapsulated OVA-expressing mRNA and the chemically modified TLR7/8 agonist C16-R848 exhibited increased tumor-associated antigen presentation, antigen-specific CD8+ T cell recruitment, and anti-tumor activity [114]. This evidence concerns the gene CD8A and neoplasm.